leadf
logo-loader
viewIXICO PLC

IXICO lands multiple contracts to battle Alzheimer's disease

IXICO PLC's (LON:IXI) Lammert Albers talks to Proactive London about landing three new contracts, with three different customers in the area of Alzheimer's disease.

Albers talks through each of the projects, which includes a phase I study, an expansion deal for a phase II clinical assessment, and it will deploy its expertise on an open-label extension phase III trial.

Albers also highlights the importance of the CTAD and the Aducanumab advisory committee meeting this Friday, which will take place virtually this year.

Quick facts: IXICO PLC

Price: 89.5 GBX

AIM:IXI
Market: AIM
Market Cap: £42.19 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: Brexit bells set to ring this Christmas Eve

The market report with Katie Pilbeam. FTSE 100 headed to the Christmas break in good cheer on the growing possibility that a Brexit deal will be announced today. The news overshadowed reports of another mutant coronavirus strain and helped London’s blue-chip index rise 19 to 6,515. Yes,...

4 weeks ago

2 min read